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ABSTRACT Induced pluripotent stem cells (iPSCs) are a new type of pluripotent cells that can be obtained by repro-
gramming animal and human differentiated cells. In this review, issues related to the nature of iPSCs are discussed 
and different methods of iPSC production are described. We particularly focused on methods of iPSC production 
without the genetic modification of the cell genome and with means for increasing the iPSC production efficiency. 
The possibility and issues related to the safety of iPSC use in cell replacement therapy of human diseases and a study 
of new medicines are considered. 
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ABBREVIATIONS ESC – embryonic stem cells, iPSCs – induced pluripotent stem cells, NSCs – neural stem cells, ASCs – 
adipose stem cells, PDFs – papillary dermal fibroblasts, CMs – cardiomyocytes, SMA – spinal muscular atrophy, SMA-
iPSCs – iPCSs derived from fibroblasts of SMA patients, GFP – green fluorescent protein, LTR – long terminal repeat
INDUCED PLURIPOTENCY
Pluripotent stem cells are a unique model for studying a 
variety of processes that occur in the early development of 
mammals and a promising tool in cell therapy of human dis-
eases. The unique nature of these cells lies in their capability, 
when cultured, for unlimited self-renewal and reproduction 
of all adult cell types in the course of their differentiation [1]. 
Pluripotency is supported by a complex system of signaling 
molecules and gene network that is specific for pluripotent 
cells. The pivotal position in the hierarchy of genes implicated 
in the maintenance of pluripotency is occupied by Oct4, Sox2, 
and Nanog genes encoding transcription factors [2, 3]. The 
mutual effect of outer signaling molecules and inner factors 
leads to the formation of a specific expression pattern, as well 
as to the epigenome state characteristic of stem cells. Both 
spontaneous and directed differentiations are associated with 
changes in the expression pattern and massive epigenetic 
transformations, leading to transcriptome and epigenome 
adjustment to a distinct cell type.
Until recently, embryonic stem cells (ESCs) were the only 
well-studied source of pluripotent stem cells. ESCs are ob-
tained from either the inner cell mass or epiblast of blasto-
cysts [4–6]. A series of protocols has been developed for the 
preparation of various cell derivatives from human ESCs. 
However, there are constraints for ESC use in cell replace-
ment therapy. The first constraint is the immune incompat-
ibility between the donor cells and the recipient, which can 
result in the rejection of transplanted cells. The second con-
straint is ethical, because the embryo dies during the isola-
tion of ESCs. The first problem can be solved by the somatic 
cell nuclear transfer into the egg cell and then obtaining the 
embryo and ESCs. The nuclear transfer leads to genome re-
programming, in which ovarian cytoplasmic factors are im-
plicated. This way of preparing pluripotent cells from certain 
individuals was called therapeutic cloning. However, this 
method is technology-intensive, and the reprogramming yield 
is very low. Moreover, this approach encounters the above-
mentioned ethic problem that, in this case, is associated with 
the generation of many human ovarian cells [7].
In 2006, the preparation of pluripotent cells by the ectopic 
expression of four genes – Oct4, Sox2, Klf4, and c-Myc – in 
both embryonic and adult murine fibroblasts was first report-
ed [8]. The pluripotent cells derived from somatic ones were 
called induced pluripotent stem cells (iPSCs). Using this set of 
factors (Oct4, Sox2, Klf4, and c-Myc), iPSCs were prepared 
later from various differentiated mouse [9–14] and human 
[15–17] cell types. Human iPSCs were obtained with a some-
what altered gene set: OCT4, SOX2, NANOG, and LIN28 [18]. 
Induced PSCs closely resemble ESCs in a broad spectrum of 
features. They possess similar morphologies and growth man-
ners and are equally sensitive to growth factors and signaling 
molecules. Like ESCs, iPSCs can differentiate in vitro into 
derivatives of all three primary germ layers (ectoderm, mes-
oderm, and endoderm) and form teratomas following their REVIEWS
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subcutaneous injection into immunodeficient mice. Murine 
iPSCs injected into blastocysts are normally included in the 
development to yield animals with a high degree of chimer-
ism. Moreover, murine iPSCs, when injected into tetraploid 
blastocycts, can develop into a whole organism [19, 20]. Thus, 
an excellent method that allows the preparation of pluripo-
tent stem cells from various somatic cell types while bypass-
ing ethical problems has been uncovered by researchers.
THE PROBLEM OF IPSC PRODUCTION EFFICIENCY AND 
APPLICATION SAFETY IN CELL REPLACEMENT THERAPY
In the first works on murine and human iPSC production, 
either retro- or lentiviral vectors were used for the delivery 
of Oct4, Sox2, Klf4, and c-Myc genes into somatic cells. The 
efficiency of transduction with retroviruses is high enough, 
although it is not the same for different cell types. Retroviral 
integration into the host genome requires a comparatively 
high division rate, which is characteristic of the relatively 
narrow spectrum of cultured cells. Moreover, the transcrip-
tion of retroviral construct under the control of a promoter 
localized in 5’LTR (long terminal repeat) is terminated when 
the somatic cell transform switches to the pluripotent state 
[21]. This feature makes retroviruses attractive in iPSC pro-
duction. Nevertheless, retroviruses possess some properties 
that make iPSCs that are produced using them improper for 
cell therapy of human diseases. First, retroviral DNA is inte-
grated into the host cell genome. The integration occurs ran-
domly; i.e., there are no specific sequences or apparent logic 
for retroviral integration. The copy number of the exogenous 
retroviral DNA that is integrated into a genome may vary to 
a great extent [15]. Retroviruses being integrated into the cell 
genome can introduce promoter elements and polyadenyla-
tion signals; they can also interpose coding sequences, thus 
affecting transcription. Second, since the transcription level 
of exogenous Oct4, Sox2, Klf4, and c-Myc in the retroviral 
construct decreases with cell transition into the pluripotent 
state, this can result in a decrease in the efficiency of the sta-
ble iPSC line production, because the switch from the exog-
enous expression of pluripotency genes to their endogenous 
expression may not occur. Third, some studies show that the 
transcription of transgenes can resume in the cells derived 
from iPSCs [22]. The high probability that the ectopic Oct4, 
Sox2, Klf4, and c-Myc gene expression will resume makes 
it impossible to apply iPSCs produced with the use of ret-
roviruses in clinical trials; moreover, these iPSCs are hardly 
applicable even for fundamental studies on reprogramming 
and pluripotency principles. Lentiviruses used for iPSC pro-
duction can also be integrated into the genome and maintain 
their transcriptional activity in pluripotent cells. One way to 
avoid this situation is to use promoters controlled by exog-
enous substances added to the culture medium, such as tet-
racycline and doxycycline, which allows the transgene tran-
scription to be regulated. iPSCs are already being produced 
using such systems [23].
Another serious problem is the gene set itself that is used 
for the induction of pluripotency [22]. The ectopic transcrip-
tion of Oct4, Sox2, Klf4, and c-Myc can lead to neoplastic de-
velopment from cells derived from iPSCs, because the ex-
pression of Oct4, Sox2, Klf4, and c-Myc genes is associated 
with the development of multiple tumors known in oncoge-
netics [22, 24]. In particular, the overexpression of Oct4 causes 
murine epithelial cell dysplasia [25], the aberrant expression 
of Sox2 causes the development of serrated polyps and mu-
cinous colon carcinomas [26], breast tumors are character-
ized by elevated expression of Klf4 [27], and the improper 
expression of c-Myc is observed in 70% of human cancers [28]. 
Tumor development is oberved in ~50% of murine chimeras 
obtained through the injection of retroviral iPSCs into blas-
tocysts, which is very likely associated with the reactivation 
of exogenous c-Myc [29, 30].
Several possible strategies exist for resolving the above-
mentioned problems:
• The search for a less carcinogenic gene set that is necessary 
and sufficient for reprogramming;
• The minimization of the number of genes required for re-
programming and searching for the nongenetic factors fa-
cilitating it;
• The search for systems allowing the elimination of the ex-
ogenous DNA from the host cell genome after the repro-
gramming;
• The development of delivery protocols for nonintegrated 
genetic constructs;
• The search for ways to reprogram somatic cells using re-
combinant proteins.
POSSIBLE GENE SUBSTITUENTS FOR C-MYC 
AND KLF4 IN IPSC PREPARATION
The ectopic expression of c-Myc and Klf4 genes is the most 
dangerous because of the high probability that malignant tu-
mors will develop [22]. Hence the necessity to find other genes 
that could substitute c-Myc and Klf4 in iPSC production. It 
has been reported that these genes can be successfully substi-
tuted by NANOG and LIN28 for reprogramming human so-
matic cells [18]. iPSCs were prepared from murine embryonic 
fibroblasts by the overexpression of Oct4 and Sox2, as well as 
the Esrrb gene encoding the murine orphan nuclear receptor 
beta. It has already been shown that Esrrb, which acts as a 
transcription activator of Oct4, Sox2, and Nanog, is necessary 
for the self-renewal and maintenance of the pluripotency of 
murine ESCs. Moreover, Esrrb can exert a positive control 
over Klf4. Thus, the genes causing elevated carcinogenicity of 
both iPSCs and their derivatives can be successfully replaced 
with less dangerous ones [31].
MEANS FOR INCREASING THE PRODUCTION 
EFFICIENCY OF IPSCS 
The Most Effectively Reprogrammed Cell Lines
Murine and human iPSCs can be obtained from fibroblasts 
using the factors Oct4, Sox2, and Klf4, but without c-Myc. 
However, in this case, reprogramming decelerates and an es-
sential shortcoming of stable iPSC clones is observed [32, 33]. 
The reduction of a number of necessary factors without any 
decrease in efficiency is possible when iPSCs are produced 
from murine and human neural stem cells (NSCs) [12, 34, 35]. 
For instance, iPSCs were produced from NSCs isolated from 
adult murine brain using two factors, Oct4 and Klf4, as well 
as even Oct4 by itself [12, 34]. Later, human iPSCs were pro-
duced by the reprogramming of fetal NSCs transduced with 
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that the irrelevance of Sox2, Klf4, and c-Myc is due to the 
high endogenous expression level of these genes in NSCs.
Successful reprogramming was also achieved in experi-
ments with other cell lines, in particular, melanocytes of neu-
roectodermal genesis [36]. Both murine and human melano-
cytes are characterized by a considerable expression level 
of the Sox2 gene, especially at early passages. iPSCs from 
murine and human melanocytes were produced without 
the use of Sox2 or c-Myc. However, the yield of iPSC clones 
produced from murine melanocytes was lower (0.03% with-
out Sox2 and 0.02% without c-Myc) in comparison with that 
achieved when all four factors were applied to melanocytes 
(0.19%) and fibroblasts (0.056%). A decreased efficiency with-
out Sox2 or c-Myc was observed in human melanocyte repro-
gramming (0.05% with all four factors and 0.01% without ei-
ther Sox2 or c-Myc). All attempts to obtain stable iPSC clones 
in the absence of both Sox2 and c-Myc were unsuccessful [36]. 
Thus, the minimization of the number of factors required for 
iPSC preparation can be achieved by choosing the proper so-
matic cell type that most effectively undergoes reprogram-
ming under the action of fewer factors, for example, due to 
the endogenous expression of “pluripotency genes.” However, 
if human iPSCs are necessary, these somatic cells should be 
easily accessible and well-cultured and their method of isola-
tion should be as noninvasive as possible.
One of these cell types can be adipose stem cells (ASCs). 
This is a heterogeneous group of multipotent cells which can 
be relatively easily isolated in large amounts from adipose 
tissue following liposuction. Human iPSCs were successfully 
produced from ASCs with a twofold reprogramming rate and 
20-fold efficiency (0.2%), exceeding those of fibroblasts [37].
However, more accessible resources for the effective pro-
duction of human iPSCs are keratinocytes. When compared 
with fibroblasts, human iPSC production from keratinocytes 
demonstrated a 100-fold greater efficiency and a twofold 
higher reprogramming rate [38].
It has recently been found that the reprogramming of mu-
rine papillary dermal fibroblasts (PDFs) into iPSCs can be 
highly effective with the overexpression of only two genes, 
Oct4 and Klf4, inserted into retroviral vectors [39]. PDFs are 
specialized cells of mesodermal genesis surrounding the stem 
cells of hair follicles. One characteristic feature of these cells 
is the endogenous expression of Sox2, Klf4, and c-Myc genes, 
as well as the gene-encoding alkaline phosphatase, one of the 
murine and human ESC markers. PDFs can be easily separat-
ed from other cell types by FACS (fluorescence-activated cell 
sorting) using life staining with antibodies against the surface 
antigens characteristic of one or another cell type. The PDF 
reprogramming efficiency with the use of four factors (Oct4, 
Sox2, Klf4, and c-Myc) retroviral vectors is 1.38%, which is 
1,000-fold higher than the skin fibroblast reprogramming ef-
ficiency in the same system. Reprogramming PDFs with two 
factors, Oct4 and Klf4, yields 0.024%, which is comparable 
to the efficiency of skin fibroblast reprogramming using all 
four factors. The efficiency of PDF reprogramming is com-
parable with that of NSCs, but PDF isolation is steady and 
far less invasive [39]. It seems likely that human PDF lines 
are also usable, and this cell type may appear to be one of the 
most promising for human iPSC production in terms of phar-
macological studies and cell replacement therapy. The use of 
such cell types undergoing more effective reprogramming, 
together with methods providing the delivery of “pluripo-
tency genes” without the integration of foreign DNA into the 
host genome and chemical compounds increasing the repro-
gramming efficiency and substituting some factors required 
for reprogramming, is particularly relevant.
Chemical Compounds Increasing Cell Reprogramming Ef-
ficiency
As was noted above, the minimization of the factors used for 
reprogramming decreases the efficiency of iPSC production. 
Nonetheless, several recent studies have shown that the use 
of genetic mechanisms, namely, the initiation of ectopic 
gene expression, can be substituted by chemical compounds, 
most of them operating at the epigenetic level. For instance, 
BIX-01294 inhibiting histone methyltransferase G9a allows 
murine fibroblast reprogramming using only two factors, 
Oct4 and Klf4, with a fivefold increased yield of iPSC clones 
in comparison with the control experiment without BIX-
01294 [40]. BIX-01294 taken in combination with another 
compound can increase the reprogramming efficiency even 
more. In particular, BIX-01294 plus BayK8644 elevated the 
yield of iPCSs 15 times, and BIX-01294 plus RG108 elevated 
it 30 times when only two reprogramming factors, Oct4 and 
Klf4, were used. RG108 is an inhibitor of DNA methyltrans-
ferases, and its role in reprogramming is apparently in ini-
tiating the more rapid and effective demethylation of pro-
moters of pluripotent cell-specific genes, whereas BayK8644 
is an antagonist of L-type calcium channels, and its role in 
reprogramming is not understood very well [40]. However, 
more considerable results were obtained in reprogramming 
murine NSCs. The use of BIX-01294 allowed a 1.5-fold in-
crease in iPSC production efficiency with two factors, Oct4 
and Klf4, in comparison with reprogramming with all four 
factors. Moreover, BIX-01294 can even substitute Oct4 in 
the reprogramming of NSCs, although the yield is very 
low [41]. Valproic (2-propylvaleric) acid inhibiting histone 
deacetylases can also substitute c-Myc in reprogramming 
murine and human fibroblasts. Valproic acid (VPA) increas-
es the reprogramming efficiency of murine fibroblasts 50 
times, and human fibroblasts increases it 10–20 times when 
three factors are used [42, 43]. Other deacetylase inhibitors, 
such as TSA (trichostatin A) and SAHA (suberoylanilide hy-
roxamic acid), also increase the reprogramming efficiency. 
TSA increases the murine fibroblast reprogramming effi-
ciency 15 times, and SAHA doubles it when all four factors 
are used [42]. Besides epigenetic regulators, the substances 
inhibiting the protein components of signaling pathways im-
plicated in the differentiation of pluripotent cells are also 
applicable in the substitution of reprogramming factors. In 
particular, inhibitors of MEK and GSK3 kinases (PD0325901 
and CHIR99021, respectively) benefit the establishment of 
the complete and stable pluripotency of iPSCs produced 
from murine NSCs using two factors, Oct4 and Klf4 [41, 
44].
It has recently been shown that antioxidants can consider-
ably increase the efficiency of somatic cell reprogramming. 
Ascorbic acid (vitamin C) can essentially influence the effi-
ciency of iPSC production from various murine and human 
somatic cell types [45]. The transduction of murine embry-REVIEWS
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onic fibroblasts (mEFs) with retroviruses carrying the Oct4, 
Sox2, and Klf4 genes results in a significant increase in the 
production level of reactive oxygen species (ROS) compared 
with that of both control and Efs tranduced with Oct4, Sox2, 
c-Myc, and Klf4. In turn, the increase in the ROS level caus-
es accelerated aging and apoptosis of the cell, which should 
influence the efficiency of cell reprogramming. By testing 
several substances possessing antioxidant activity such as vi-
tamin B1, sodium selenite, reduced glutathione, and ascorbic 
acid, the authors have found that combining these substances 
increases the yield of GFP-positive cells in EF reprogramming 
(the Gfp gene was under the control of the Oct4 gene pro-
moter). The use of individual substances has shown that only 
ascorbate possesses a pronounced capability to increase the 
level of GFP-positive cells, although other substances keep 
their ROS-decreasing ability. In all likelihood, this feature of 
ascorbates is not directly associated with its antioxidant ac-
tivity [45]. The score of GFP-positive iPSC colonies expressing 
an alkaline phosphatase has shown that the efficiency of iPSC 
production from mEFs with three factors (Oct4, Sox2, and 
Klf4) can reach 3.8% in the presence of ascorbate. When all 
four factors (Oct4, Sox2, Klf4, and c-Myc) are used together 
with ascorbate, the efficiency of iPSC production may reach 
8.75%. A similar increase in the iPSC yield was also observed 
in the reprogramming of murine breast fibroblasts; i.e., the 
effect of vitamin C is not limited by one cell type. Moreover, 
the effect of vitamin C on the reprogramming efficiency is 
more profound than that of the deacetylase inhibitor valproic 
(2-propylvaleric) acid. The mutual effect of ascorbate and 
valproate is additive; i.e., these substances have different ac-
tion mechanisms. Moreover, vitamin C facilitates the transi-
tion from pre-iPSCs to stable pluripotent cells. This feature is 
akin to the effects of PD0325901 and CHIR99021, which are 
inhibitors of MEK and GSK3 kinases, respectively. This effect 
of vitamin C expands to human cells as well [45]. Following 
the transduction of human fibroblasts with retroviruses car-
rying Oct4, Sox2, Klf4, and c-Myc and treatment with ascor-
bate, the authors prepared iPSCs with efficiencies reaching 
6.2%. The reprogramming efficiency of ASCs under the same 
conditions reached 7.06%. The mechanism of the effect that 
vitamin C has on the reprogramming efficiency is not known 
in detail. Nevertheless, the acceleration of cell proliferation 
was observed at the transitional stage of reprogramming. The 
levels of the p53 and p21 proteins decreased in cells treated 
with ascorbate, whereas the DNA repair machinery worked 
properly [45]. It is interesting that an essential decrease in the 
efficiency of iPSC production has been shown under the ac-
tion of processes initiated by p53 and p21 [46–50].
METHODS FOR IPSC PRODUCTION WITHOUT 
MODIFICATION OF THE CELL GENOME
As was mentioned above, for murine and human iPSC pro-
duction, both retro- and lentiviruses were initially used as 
delivery vectors for the genes required for cell reprogram-
ming. The main drawback of this method is the uncontrolled 
integration of viral DNA into the host cell’s genome. Several 
research groups have introduced methods for delivering 
“pluripotency genes” into the recipient cell which either do 
not integrate allogenic DNA into the host genome or elimi-
nate exogenous genetic constructs from the genome.
Cre-loxP-Mediated Recombination
To prepare iPSCs from patients with Parkinson’s disease, 
lentiviruses were used, the proviruses of which can be re-
moved from the genome by Cre-recombinase. To do this, the 
loxP-site was introduced into the lentiviral 3’LTR-regions 
containing separate reprogramming genes under the control 
of the doxycycline-inducible promoter. During viral repli-
cation, loxP was duplicated in the 5’LTR of the vector. As a 
result, the provirus integrated into the genome was flanked 
with two loxP-sites. The inserts were eliminated using the 
temporary transfection of iPSCs with a vector expressing 
Cre-recombinase [51].
In another study, murine iPSCs were produced using a 
plasmid carrying the Oct4, Sox2, Klf4I, and c-Myc genes in 
the same reading frame in which individual cDNAs were sep-
arated by sequences encoding 2А peptides, and practically 
the whole construct was flanked with loxP-sites [52]. The use 
of this vector allowed a notable decrease in the number of 
exogenous DNA inserts in the host cell’s genome and, hence, 
the simplification of their following excision [52]. It has been 
shown using lentiviruses carrying similar polycistronic con-
structs that one copy of transgene providing a high expression 
level of the exogenous factors Oct4, Sox2, Klf4, and c-Myc is 
sufficient for the reprogramming of differentiated cells into 
the pluripotent state [53, 54].
The drawback of the Cre-loxP-system is the incomplete ex-
cision of integrated sequences; at least the loxP-site remains in 
the genome, so the risk of insertion mutations remains.
Plasmid Vectors
The application of lentiviruses and plasmids carrying the 
loxP-sites required for the elimination of transgene con-
structs modifies, although insignificantly, the host cell’s 
genome. One way to avoid this is to use vector systems that 
generally do not provide for the integration of the whole 
vector or parts of it into the cell’s genome. One such system 
providing a temporary transfection with polycistronic plas-
mid vectors was used for iPSC production from mEFs [29]. A 
polycistronic plasmid carrying the Oct4, Sox2, and Klf4 gene 
cDNAs, as well as a plasmid expressing c-Myc, was trans-
fected into mEFs one, three, five, and seven days after their 
primary seeding. Fibroblasts were passaged on the ninth day, 
and the iPSC colonies were selected on the 25th day. Seven 
out of ten experiments succeeded in producing GFP-positive 
colonies (the Gfp gene was under the control of the Nanog 
gene promoter). The iPSCs that were obtained were similar 
in their features to murine ESCs and did not contain inserts of 
the used DNA constructs in their genomes. Therefore, it was 
shown that wholesome murine iPSCs that do not carry trans-
genes can be reproducibly produced, and that the temporary 
overexpression of Oct4, Sox2, Klf4, and c-Myc is sufficient for 
reprogramming. The main drawback of this method is its low 
yield. In ten experiments the yield varied from 1 to 29 iPSC 
colonies per ten million fibroblasts, whereas up to 1,000 colo-
nies per ten millions were obtained in the same study using 
retroviral constructs [29].
Episomal Vectors
Human iPSCs were successfully produced from skin fibrob-
lasts using single transfection with polycistronic episomal 22 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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constructs carrying various combinations of Oct4, Sox2, Na-
nog, Klf4, c-Myc, Lin28, and SV40LT genes. These constructs 
were designed on the basis of the oriP/EBNA1 (Epstein-Barr 
nuclear antigen-1) vector [55]. The oriP/EBNA1 vector con-
tains the IRES2 linker sequence allowing the expression of 
several individual cDNAs (encoding the genes required for 
successful reprogramming in this case) into one polycistronic 
mRNA from which several proteins are translated. The oriP/
EBNA1 vector is also characterized by low-copy representa-
tion in the cells of primates and can be replicated once per cell 
cycle (hence, it is not rapidly eliminated, the way common 
plasmids are). Under nonselective conditions, the plasmid 
is eliminated at a rate of about 5% per cell cycle [56]. In this 
work, the broad spectrum of the reprogramming factor com-
binations was tested, resulting in the best reprogramming 
efficiency with cotransfection with three episomes containing 
the following gene sets: Oct4 + Sox2 + Nanog + Klf4, Oct4 + 
Sox2 + SV40LT + Klf4, and c-Myc + Lin28. SV40LT (SV40 
large T gene) neutralizes the possible toxic effect of с-Мус 
overexpression [57]. The authors have shown that wholesome 
iPSCs possessing all features of pluripotent cells can be pro-
duced following the temporary expression of a certain gene 
combination in human somatic cells without the integration 
of episomal DNA into the genome. However, as in the case 
when plasmid vectors are being used, this way of reprogram-
ming is characterized by low efficiency. In separate experi-
ments the authors obtained from 3 to 6 stable iPSC colonies 
per 106 transfected fibroblasts [55]. Despite the fact that skin 
fibroblasts are well-cultured and accessible, the search for 
other cell types which are relatively better cultured and more 
effectively subject themselves to reprogramming through 
this method is very likely required. Another drawback of the 
given system is that this type of episome is unequally main-
tained in different cell types.
PiggyBac-Transposition
One promising system used for iPSC production without any 
modification of the host genome is based on DNA transposons. 
So-called PiggyBac-transposons containing 2А-linkered re-
programming genes localized between the 5’- and 3’-terminal 
repeats were used for iPSC production from fibroblasts. The 
integration of the given constructs into the genome occurs 
due to mutual transfection with a plasmid encoding trans-
posase. Following reprogramming due to the temporary ex-
pression of transposase, the elimination of inserts from the 
genome took place [58, 59]. One advantage of the PiggyBac 
system on Cre-loxP is that the exogenous DNA is completely 
removed [60].
However, despite the relatively high efficiency of exog-
enous DNA excision from the genome by PiggyBac-transpo-
sition, the removal of a large number of transposon copies is 
hardly achievable.
Nonintegrating Viral Vectors
Murine iPSCs were successfully produced from hepatocytes 
and fibroblasts using four adenoviral vectors nonintegrating 
into the genome and carrying the Oct4, Sox2, Klf4, and c-
Myc genes. An analysis of the obtained iPSCs has shown that 
they are similar to murine ESCs in their properties (teratoma 
formation, gene promoter DNA methylation, and the expres-
sion of pluripotent markers), but they do not carry insertions 
of viral DNA in their genomes [61]. Later, human fibroblast-
derived iPSCs were produced using this method [62].
The authors of this paper cited the postulate that the use 
of adenoviral vectors allows the production of iPSCs, which 
are suitable for use without the risk of viral or oncogenic ac-
tivity. Its very low yield (0.0001–0.001%), the deceleration of 
reprogramming, and the probability of tetraploid cell forma-
tion are the drawbacks of the method. Not all cell types are 
equally sensitive to transduction with adenoviruses.
Another method of gene delivery based on viral vectors 
was recently employed for the production of human iPSCs. 
The sendai-virus (SeV)-based vector was used in this case 
[63]. SeV is a single-stranded RNA virus which does not mod-
ify the genome of recipient cells; it seems to be a good vector 
for the expression of reprogramming factors. Vectors contain-
ing either all “pluripotency factors” or three of them (without 
с-Мус) were used for reprogramming the human fibroblast. 
The construct based on SeV is eliminated later in the course 
of cell proliferation. It is possible to remove cells with the inte-
grated provirus via negative selection against the surface HN 
antigen exposed on the infected cells. The authors postulate 
that reprogramming technology based on SeV will enable the 
production of clinically applicable human iPSCs [63].
Cell Transduction with Recombinant Proteins
Although the methods for iPSC production without gene 
modification of the cell’s genome (adenoviral vectors, plasmid 
gene transfer, etc.) are elaborated, the theoretical possibility 
for exogenous DNA integration into the host cell’s genome 
still exists. The mutagenic potential of the substances used 
presently for enhancing iPSC production efficiency has not 
been studied in detail. Fully checking iPSC genomes for ex-
ogenous DNA inserts and other mutations is a difficult task, 
which becomes impossible to solve in bulk culturing of multi-
ple lines. The use of protein factors delivered into a differenti-
ated cell instead of exogenous DNA may solve this problem. 
Two reports have been published to date in which murine 
and human iPSCs were produced using the recombinant 
OCT4, SOX2, KLF4, and C-MYC proteins [64, 65]. The meth-
od used to deliver the protein into the cell is based on the abil-
ity of peptides enriched with basic residues (such as arginine 
and lysine) to penetrate the cell’s membrane. Murine iPSCs 
were produced using the recombinant OCT4, SOX2, KLF4, 
and C-MYC proteins containing eleven C-terminal arginine 
residues and expressed in E. coli. The authors succeeded in 
producing murine iPSCs during four rounds of protein trans-
duction into embryonic fibroblasts [65]. However, iPSCs were 
only produced when the cells were additionally treated with 
2-propylvalerate (the deacetylase inhibitor). The same princi-
ple was used for the production of human iPSCs, but protein 
expression was carried out in human HEK293 cells, and the 
proteins were expressed with a fragment of nine arginins at 
the protein C-end. Researchers have succeeded in produc-
ing human iPSCs after six transduction rounds without any 
additional treatment [64]. The efficiency of producing hu-
man iPSC in this way was 0.001%, which is one order lower 
than the reprogramming efficiency with retroviruses. De-
spite some drawbacks, this method is very promising for the 
production of patient-specific iPSCs.REVIEWS
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INDUCED PLURIPOTENT STEM CELLS AS A 
MODEL FOR PATHOGENESIS STUDIES AND A 
SOURCE OF CELL REPLACEMENT THERAPY
The first lines of human pluripotent ESCs were produced in 
1998 [6]. In line with the obvious fundamental importance 
of embryonic stem cell studies with regard to the multi-
ple processes taking place in early embryogenesis, much 
of the interest of investigators is associated with the pos-
sibility of using ESCs and their derivatives as models for 
the pathogenesis of human diseases, new drugs testing, 
and cell replacement therapy. Substantial progress is being 
achieved in studies on directed human ESC differentiation 
and the possibility of using them to correct degenerative 
disorders. Functional cell types, such as motor dopaminer-
gic neurons, cardiomyocytes, and hematopoietic cell pro-
genitors, can be produced as a result of ESC differentiation. 
These cell derivatives, judging from their biochemical and 
physiological properties, are potentially applicable for the 
therapy of cardiovascular disorders, nervous system dis-
eases, and human hematological disorders [66]. Moreover, 
derivatives produced from ESCs have been successfully 
used for treating diseases modeled on animals. Therefore, 
blood-cell progenitors produced from ESCs were success-
fully used for correcting immune deficiency in mice. Visual 
functions were restored in blind mice using photoreceptors 
produced from human ESCs, and the normal functioning 
of the nervous system was restored in rats modeling Par-
kinson’s disease using the dopaminergic neurons produced 
from human ESCs [67–70]. Despite obvious success, the 
full-scale application of ESCs in therapy and the modeling 
of disorders still carry difficulties, because of the necessity 
to create ESC banks corresponding to all HLA-haplotypes, 
which is practically unrealistic and hindered by technical 
and ethical problems.
Design of an experiment on repairing the mutant phenotype in mice modeling sickle cell anemia development [2]. Fibroblasts isolated 
from the tail of a mouse (1) carrying a mutant allele of the gene encoding the human hemoglobin -chain (hs) were used for iPSC 
production (2). The mutation was then repaired in iPSCs by means of homological recombination (3) followed by cell differentiation 
via the embryoid body formation (4). The directed differentiation of the embryoid body cells led to hematopoietic precursor cells (5) 
that were subsequently introduced into a mouse exposed to ionizing radiation (6).
hS/ hS fibroblasts
Transduction with retroviral vector 
(Oct4, Sox2, Klf4, c-Myc)
hS/ hS iPSCs
hS/ hS iPSCs
hS/ hS iPSCs
Repairing defect 
of the hS gene
Differentiation
Embryoid bodies
Hematopoietic precursor 
cells
5
6
1
2
3
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Table. iPSC lines produced by reprogramming somatic cells from patients with various diseases
Disease Causative factor Reprogrammed cell type Means of reprogramming Ref. 
No
Adenosine deami-
nase deficiency
Replacement of GGG with AGG in 
exon 7 resulting in G216R substitution 
or deletion of GAAGA in exon 10 of the 
ADA (adenosine deaminase) gene
Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Type 3 Gaucher’s 
disease
Replacement of AAC with AGC in exon 
9 or insertion of G at position 84 of the 
GBA (β-acid glucosidase) gene cDNA
Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Duchenne muscu-
lar dystrophy
Deletion of exons 45-52 of the DMD 
(dystrophin) gene
Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Becker muscular 
dystrophy Unidentified mutation in the DMD gene Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Down syndrome Trisomy of chromosome 21 Skin fibroblasts, karyotype 
47,XY,+21
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Parkinson’s 
disease Multifactorial disease
Skin fibroblasts, karyotype 
46,XY 
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Fibroblasts; the age of the 
patient at the moment of 
biopsy was 53–85 years, 
karyotypes: 46,XY (six 
lines) and 46,XX (one line)
Transduction with lentiviruses carrying the 
OCT4, SOX2, and KLF4 or OCT4, SOX2, 
KLF4 and c-MYC genes. Viral LTRs contained 
LoxP sites required for the excision of the 
exogenous construct from the cell genome
[51]
Diabetes mellitus 
type 1 (juvenile 
diabetes)
Multifactorial disease Skin fibroblasts, karyotype 
46,XX
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Shwachman–
Bodian–Diamond 
syndrome
Point mutations in the SBDS 
(Shwachman–Bodian–Diamond 
Syndrome) gene
Bone marrow mesenchy-
mal cells, karyotype 46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Huntington’s 
disease
CAG repeat expansion in the 
Huntington gene from normal 11–34 
copies to 37–100 and more
Skin fibroblasts, karyotype 
46,XX
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [91]
Lesch–Nyhan 
syndrome
Mutations in the HPRT (hypoxanthine-
guanine phosphoribosyltransferase) gene
Skin fibroblasts, karyotype 
46,XX 
Transduction with retroviruses carrying 
the OCT4, SOX2, KLF4, and c-MYC cDNAs. 
One line was produced by transduction with 
doxycyclin-controlled lentiviral vectors 
carrying the OCT4, SOX2, KLF4, c-MYC, and 
NANOG cDNAs 
[91]
 Fibroblasts, karyotype 
46,XX
Transduction with lentiviruses carrying the 
OCT4, SOX2, and KLF4 genes. Viral LTRs 
contained LoxP sites required for the excision 
of exogenous construct from cell genome
[51]
Dyskeratosis con-
genita (Zinsser-
Engman-Cole 
syndrome)
Mutations in the DKC1 (Dyskeratosis 
congenita) gene 
Fibroblasts, karyotype 
46,XX
Transduction with lentiviruses carrying the 
OCT4, SOX2, and KLF4 genes [51]
Spinal muscular 
atrophy
Mutations in the SMN1 (Survival Motor 
Neuron 1) gene resulting in a decreased 
level of the SMN protein
Skin fibroblasts, karyotype 
46,XY
Transduction with lentiviruses carrying the 
OCT4, SOX2, NANOG, and LIN28 cDNAs [89]
Familial dysau-
tonomia
Mutation in the IKBKAP (inhibitor of 
kappa light polypeptide gene enhancer 
in B-cells; IkB kinase complex associ-
ated protein) gene resulted in shift 
splicing that generates a transcript 
lacking exon 20
Lung and skin fibroblasts, 
karyotypes 46,XX and 
46,XY
Transduction with lentiviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [90]
-Thalassemia Mutations in the HBB (haemoglobin 
beta) gene
Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [92]
Diabetes mellitus 
type 1 (juvenile 
diabetes)
Multifactorial disease Skin fibroblasts, karyotype 
46,XY
Transduction with retroviruses carrying the 
OCT4, SOX2, and KLF4 cDNAs [93]
Amyotrophic 
lateral sclerosis
L144F substitution in superoxide dis-
mutase encoded by the dominant allele 
of the SOD1 (Superoxide dismutase 1) 
gene; this mutation is associated with 
slow disease progression
Skin fibroblasts, karyotype 
46,XX
Transduction with retroviruses carrying the 
OCT4, SOX2, KLF4, and c-MYC cDNAs [94]
Fanconi anemia At present, 13 genes whose mutations 
cause Fanconi anemia are known
Skin fibroblasts and 
epidermal keratinocytes
Transduction with retroviruses carrying 
the OCT4, SOX2, KLF4, and c-MYC cDNAs. 
iPSCs from keratinocytes were produced 
without c-MYC
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Induced pluripotent stem cells can become an alternative 
for ESCs in the area of clinical application of cell replacement 
therapy and screening for new pharmaceuticals. iPSCs closely 
resemble ESCs and, at the same time, can be produced in al-
most unlimited amounts from the differentiated cells of each 
patient. Despite the fact that the first iPSCs were produced 
relatively recently, work on directed iPSC differentiation 
and the production of patient-specific iPSCs is intensive, and 
progress in this field is obvious.
Dopamine and motor neurons were produced from human 
iPSCs by directed differentiation in vitro [71, 72]. These types 
of neurons are damaged in many inherited or acquired hu-
man diseases, such as spinal cord injury, Parkinson’s disease, 
spinal muscular atrophy, and amyotrophic lateral sclerosis. 
Some investigators have succeeded in producing various 
retinal cells from murine and human iPSCs [73–75]. Human 
iPSCs have been shown to be spontaneously differentiated in 
vitro into the cells of retinal pigment epithelium [76]. Another 
group of investigators has demonstrated that treating human 
and murine iPSCs with WNT and NODAL antagonists in a 
suspended culture induces the appearance of markers of cell 
progenitors and pigment epithelium cells. Further treating 
the cells with retinoic acid and taurine activates the appear-
ance of cells expressing photoreceptor markers [75].
Several research groups have produced functional car-
diomyocytes (CMs) in vitro from murine and human iP-
SCs [77–81]. Cardiomyocytes produced from iPSC are very 
similar in characteristics (morphology, marker expression, 
electrophysiological features, and sensitivity to chemicals) 
to the CMs of cardiac muscle and to CMs produced from dif-
ferentiated ESCs. Moreover, murine iPSCs, when injected, 
can repair muscle and endothelial cardiac tissues damaged by 
cardiac infarction [77].
Hepatocyte-like cell derivatives, dendritic cells, macro-
phages, insulin-producing cell clusters similar to the duode-
nal islets of Langerhans, and hematopoietic and endothelial 
cells are currently produced from murine and human iPSCs, 
in addition to the already-listed types of differentiated cells 
[82–85].
In addition to directed differentiation in vitro, investiga-
tors apply much effort at producing patient-specific iPSCs. 
The availability of pluripotent cells from individual patients 
makes it possible to study pathogenesis and carry out experi-
ments on the therapy of inherited diseases, the development 
of which is associated with distinct cell types that are hard 
to obtain by biopsy: so the use of iPSCs provides almost an 
unlimited resource for these investigations. Recently, the 
possibility of treating diseases using iPSCs was successfully 
demonstrated, and the design of the experiment is presented 
in the figure. A mutant allele was substituted with a normal 
allele via homologous recombination in murine fibroblasts 
representing a model of human sickle cell anemia. iPSCs were 
produced from “repaired” fibroblasts and then differenti-
ated into hematopoietic cell precursors. The hematopoietic 
precursors were then injected into a mouse from which the 
skin fibroblasts were initially isolated (see figure). As a result, 
the initial pathological phenotype was substantially corrected 
[86]. A similar approach was applied to the fibroblasts and 
keratinocytes of a patient with Fanconi’s anemia. The normal 
allele of the mutant gene producing anemia was introduced 
into a somatic cell genome using a lentivirus, and then iPSCs 
were obtained from these cells. iPSCs carrying the normal al-
lele were differentiated into hematopoietic cells maintaining 
a normal phenotype [87]. The use of lentiviruses is unambigu-
ously impossible when producing cells to be introduced into 
the human body due to their oncogenic potential. However, 
new relatively safe methods of genome manipulation are cur-
rently being developed; for instance, the use of synthetic nu-
cleases containing zinc finger domains allowing the effective 
correction of genetic defects in vitro [88].
The induced pluripotent stem cells are an excellent model 
for pathogenetic studies at the cell level and testing com-
pounds possessing a possible therapeutic effect.
The induced pluripotent stem cells were produced from 
the fibroblasts of a patient with spinal muscular atrophy 
(SMA) (SMA-iPSCs). SMA is an autosomal recessive disease 
caused by a mutation in the SMN1 (survival motor neuron 1) 
gene, which is manifested as the selective nonviability of low-
er α-motor neurons. Patients with this disorder usually die at 
the age of about two years. Existing experimental models of 
this disorder based on the use of flatworms, drosophila, and 
mice are not satisfactory. The available fibroblast lines from 
patients with SMA cannot provide the necessary data on the 
pathogenesis of this disorder either. It was shown that motor 
neurons produced from SMA-iPSCs can retain the features 
of SMA development, selective neuronal death, and the lack 
of SMN1 transcription. Moreover, the authors succeeded in 
elevating the SMN protein level and aggregation (encoded 
by the SMN2 gene, whose expression can compensate for the 
shortage in the SMN1 protein) in response to the treatment 
of motor neurons and astrocytes produced from SMA-iPSCs 
with valproate and torbomycin [89]. iPSCs and their deriva-
tives can serve as objects for pharmacological studies, as has 
been demonstrated on iPSCs from patients with familial dy-
sautonomia (FDA) [90]. FDA is an inherited autosomal reces-
sive disorder manifested as the degeneration of sensor and 
autonomous neurons. This is due to a mutation causing the 
tissue-specific splicing of the IKBKAP gene, resulting in a 
decrease in the level of the full-length IKAP protein. iPSCs 
were produced from fibroblasts of patients with FDA. They 
possessed all features of pluripotent cells. Neural derivatives 
produced from these cells had signs of FDA pathogenesis and 
low levels of the full-length IKBKAP transcript. The authors 
studied the effect of three substances, kinetin, epigallocate-
chin gallate, and tocotrienol, on the parameters associated 
with FDA pathogenesis. Only kinetin has been shown to in-
duce an increase in the level of full-length IKBKAP transcript. 
Prolonged treatment with kinetin induces an increase in the 
level of neuronal differentiation and expression of peripheral 
neuronal markers.
Currently, a broad spectrum of iPSCs is produced from 
patients with various inherited pathologies and multifactorial 
disorders, such as Parkinson’s disease, Down syndrome, type 
1 diabetes, Duchenne muscular dystrophy, β-talassemia, etc., 
which are often lethal and can scarcely be treated with rou-
tine therapy [51, 87, 89, 91–94]. The data on iPSCs produced 
by reprogramming somatic cells from patients with various 
pathologies are given in the table.
One can confidently state that both iPSCs themselves 
and their derivatives are potent instruments applicable in 26 | ACTA NATURAE |  VOL. 2  № 2 (5)  2010
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biomedicine, cell replacement therapy, pharmacology, and 
toxicology. However, the safe application of iPSC-based tech-
nologies requires the use of methods of iPSCs production and 
their directed differentiation which minimize both the pos-
sibility of mutations in cell genomes under in vitro cultur-
ing and the probability of malignant transformation of the 
injected cells. The development of methods for human iPSC 
culturing without the use of animal cells (for instance, the 
feeder layer of murine fibroblasts) is necessary; they make a 
viral-origin pathogen transfer from animals to humans im-
possible. There is a need for the maximum standardization of 
conditions for cell culturing and differentiation. 
This study was supported by the Russian Academy of 
Sciences’ Presidium Program “Molecular and Cell Biology.”
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